Last reviewed · How we verify
Autologous, DNP-Modified Vaccine
At a glance
| Generic name | Autologous, DNP-Modified Vaccine |
|---|---|
| Also known as | MVax |
| Sponsor | AVAX Technologies |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma (PHASE2)
- M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma (PHASE3)
- Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma (PHASE1, PHASE2)
- Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer (PHASE1, PHASE2)
- DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer (PHASE2)
- Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous, DNP-Modified Vaccine CI brief — competitive landscape report
- Autologous, DNP-Modified Vaccine updates RSS · CI watch RSS
- AVAX Technologies portfolio CI